DENTSPLY SIRONA Inc. $XRAY Shares Sold by Cooke & Bieler LP

Cooke & Bieler LP cut its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 26.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,089,385 shares of the medical instruments supplier’s stock after selling 1,838,530 shares during the period. Cooke & Bieler LP owned about 2.55% of DENTSPLY SIRONA worth $45,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of DENTSPLY SIRONA during the second quarter valued at approximately $283,405,000. Southpoint Capital Advisors LP purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter worth approximately $116,000,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter worth about $47,780,000. Paradigm Capital Management Inc. NY purchased a new position in shares of DENTSPLY SIRONA during the second quarter valued at approximately $39,775,000. Finally, Bank of America Corp DE purchased a new position in DENTSPLY SIRONA during the 2nd quarter valued at $31,001,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Wall Street Analyst Weigh In

XRAY has been the subject of several research analyst reports. Piper Sandler decreased their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Friday, October 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Barclays lifted their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research note on Monday, August 24th. BMO Capital Markets reduced their price objective on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research note on Thursday, September 17th. Finally, Leerink Partners decreased their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a research note on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $12.92.

DENTSPLY SIRONA Stock Up 2.4%

XRAY stock opened at $9.08 on Thursday. The firm has a market cap of $1.81 billion, a PE ratio of -3.30, a PEG ratio of 1.13 and a beta of 0.87. DENTSPLY SIRONA Inc. has a one year low of $8.32 and a one year high of $14.76. The firm’s 50 day moving average price is $9.95 and its 200-day moving average price is $10.97. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.39 EPS for the current year.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.